Thomas Grellety

1.5k total citations · 1 hit paper
42 papers, 613 citations indexed

About

Thomas Grellety is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Thomas Grellety has authored 42 papers receiving a total of 613 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Thomas Grellety's work include Advanced Breast Cancer Therapies (7 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Thomas Grellety is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Thomas Grellety collaborates with scholars based in France, Belgium and United States. Thomas Grellety's co-authors include Antoîne Italiano, Marina Pulido, Sophie Cousin, Nicolas Penel, Sophie Piperno‐Neumann, Emmanuelle Bompas, Maud Toulmonde, Alban Bessede, Jean‐Yves Blay and Julien Adam and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Thomas Grellety

36 papers receiving 609 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures

2025 18 citations Florent Peyraud, Lucile Vanhersecke et al. Cell Reports Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Grellety France	12	399	274	149	113	96	42	613
Marina Pulido France	10	315 0.8×	275 1.0×	134 0.9×	73 0.6×	84 0.9×	25	522
A.R. Abdul Razak Canada	11	435 1.1×	283 1.0×	105 0.7×	211 1.9×	75 0.8×	26	760
U. Matulonis United States	9	342 0.9×	252 0.9×	126 0.8×	125 1.1×	46 0.5×	33	596
Emi Noguchi Japan	12	352 0.9×	208 0.8×	76 0.5×	115 1.0×	120 1.3×	63	608
Suneel D. Kamath United States	14	435 1.1×	225 0.8×	115 0.8×	180 1.6×	116 1.2×	57	767
Maria Marples United Kingdom	10	512 1.3×	357 1.3×	69 0.5×	176 1.6×	41 0.4×	31	722
Virginia Arrazubi Spain	12	372 0.9×	235 0.9×	52 0.3×	136 1.2×	109 1.1×	48	641
Lifeng Sun China	15	195 0.5×	120 0.4×	88 0.6×	195 1.7×	147 1.5×	39	558
Yi Que China	14	347 0.9×	208 0.8×	139 0.9×	193 1.7×	84 0.9×	51	595
Eivind Smeland Norway	14	231 0.6×	195 0.7×	93 0.6×	98 0.9×	43 0.4×	22	441

Countries citing papers authored by Thomas Grellety

Since Specialization

Citations

This map shows the geographic impact of Thomas Grellety's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Grellety with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Grellety more than expected).

Fields of papers citing papers by Thomas Grellety

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Grellety. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Grellety. The network helps show where Thomas Grellety may publish in the future.

Co-authorship network of co-authors of Thomas Grellety

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Grellety. A scholar is included among the top collaborators of Thomas Grellety based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Grellety. Thomas Grellety is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Audureau, Étienne, Pierre Soubeyran, Claudia Martinez‐Tapia, et al.. (2025). Machine Learning to Predict Mortality in Older Patients With Cancer: Development and External Validation of the Geriatric Cancer Scoring System Using Two Large French Cohorts. Journal of Clinical Oncology. 43(12). 1429–1440. 2 indexed citations

Peyraud, Florent, Lucile Vanhersecke, Jean‐Michel Coindre, et al.. (2025). Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures. Cell Reports Medicine. 6(2). 101934–101934. 18 indexed citations breakdown →

Grellety, Thomas, Carine Bellera, Coralie Cantarel, et al.. (2025). Important aspects of care and priorities of older patients with cancer: The PRIORITY multicenter cohort study. Journal of Geriatric Oncology. 102812–102812.

Franzoi, Maria Alice, Arlindo R. Ferreira, Thomas Grellety, et al.. (2024). Abstract PO1-10-10: Leveraging technology to optimize symptom management and patient empowerment in routine breast cancer care: implementation of a remote patient monitoring (RPM) pathway across 24 hospitals in Europe. Cancer Research. 84(9_Supplement). PO1–10.

Franzoi, Maria Alice, Arlindo R. Ferreira, Antoine Lemaire, et al.. (2024). Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium. The Lancet Regional Health - Europe. 44. 101005–101005. 15 indexed citations

Bertrand, Nicolas, Thomas Grellety, Romain Rivoirard, et al.. (2024). 1907P Deployment of remote patient monitoring in older patients: A real-world experience from 2419 patients across 58 centres in France and Belgium. Annals of Oncology. 35. S1111–S1112.

Franzoi, Maria Alice, Mario Di Palma, Thomas Grellety, et al.. (2024). The impact of self-reported social determinants of health (SDOH) on patient engagement and symptom burden across a remote patient monitoring (RPM) pathway in 42 European hospitals.. Journal of Clinical Oncology. 42(16_suppl). 1506–1506. 2 indexed citations

Peyraud, Florent, Jean‐Philippe Guégan, Lucile Vanhersecke, et al.. (2023). Abstract 6767: Cancer-associated fibroblasts promote T-cell exclusion and resistance to immunotherapy in non-small cell lung cancer with tertiary lymphoid structures. Cancer Research. 83(7_Supplement). 6767–6767. 1 indexed citations

Bonnefoi, Hervé, Anthony Gonçalvès, Marc Debled, et al.. (2023). Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data. The Breast. 73. 103667–103667. 6 indexed citations

10.

Grellety, Thomas, Alain Ravaud, G. Ganem, et al.. (2020). Infection à SARS-CoV-2/COVID 19 et cancers solides : synthèse des recommandations à l’attention des professionnels de santé. Bulletin du Cancer. 107(4). 400–402. 16 indexed citations

11.

Bonnefoi, Hervé, Gaëtan MacGrogan, Coralie Poncet, et al.. (2019). Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. British Journal of Cancer. 120(9). 913–921. 13 indexed citations

12.

Audureau, Étienne, Pierre Soubeyran, Claudia Martinez‐Tapia, et al.. (2019). Using machine learning to predict mortality in older patients with cancer: Decision tree and random forest analyses from the ELCAPA and ONCODAGE prospective cohorts.. Journal of Clinical Oncology. 37(15_suppl). 11516–11516. 2 indexed citations

13.

Grellety, Thomas, Céline Callens, Élodie Richard, et al.. (2018). Enhancing Abiraterone Acetate Efficacy in Androgen Receptor–positive Triple-negative Breast Cancer: Chk1 as a Potential Target. Clinical Cancer Research. 25(2). 856–867. 19 indexed citations

14.

Grellety, Thomas, Carlo Lucchesi, Isabelle Hostein, et al.. (2017). High-depth sequencing of paired primary and metastatic tumours: Implications for personalised medicine. European Journal of Cancer. 84. 250–256. 6 indexed citations

15.

Richard, Élodie, Thomas Grellety, Valérie Velasco, et al.. (2016). The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours. The Journal of Pathology. 240(3). 256–261. 28 indexed citations

16.

Chakiba, Camille, Thomas Grellety, Sophie Cousin, & Antoîne Italiano. (2016). Risks and benefits of phase 1 oncology trials in the era of personalized medicine. Annals of Oncology. 27. vi476–vi476. 1 indexed citations

17.

Grellety, Thomas, Audrey Gros, Florence Pédeutour, et al.. (2016). Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 469(4). 459–464. 4 indexed citations

18.

Pouessel, Damien, Sylvie Chevret, Frédéric Rolland, et al.. (2015). Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?. European Journal of Cancer. 54. 69–74. 11 indexed citations

19.

Grellety, Thomas, et al.. (2014). Quality of reporting of phase II trials: a focus on highly ranked oncology journals. Annals of Oncology. 25(2). 536–541. 15 indexed citations

20.

Daste, Amaury, Thomas Grellety, Marine Gross‐Goupil, & Alain Ravaud. (2013). Protein kinase inhibitors in renal cell carcinoma. Expert Opinion on Pharmacotherapy. 15(3). 337–351. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact